Galvani E, Mundra P, Valpione S, et al. Low tumour heterogeneity but not mutational burden correlates with response to anti-PD-1 treatment in a mouse model of melanoma. SMR 2017, abstract SMR4-04.
Zorginstituut adviseert over toelating pembrolizumab (Keytruda) bij TNBC
mei 2024 | Borstkanker